marked.bio

menin inhibitor ยท small molecule

enzomenib

1 active trials across 2 of our biomarkers, targeting menin. Not approved for any biomarker on marked.bio yet.

Also known as DSP-5336.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
FLT3 mutation (ITD/TKD) 1 1 Phase 1/2
NPM1 mutation 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of enzomenib.

  1. Sumitomo Pharma America 1

Trials

1 of 1 trials shown

  1. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    Recruiting Phase 1/2 Sumitomo Pharma America Started 2022Primary completion 2027-06 NCT04988555

    enzomenibazolesvenetoclaxgilteritinib FDA EUazacitidineIntensive chemotherapy with 7 + 3

    Have MLLr or NPM1m AND any of the following FLT3 mutations: FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.

    FLT3 mutation (ITD/TKD)NPM1 mutationLeukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes